1. Becares M, Pascual-Iglesias A, Nogales A, et al. Mutagenesis of coronavirus nsp14 reveals its potential role in modulation of the innate immune response. J. Virol. 2016;90:5399–5414. doi:10.1128/JVI.03259-15.
2. Miller A, Reandelar MJ, Fasciglione K, et al. Correlation between universal BCG vaccination policy and reduced morbility and mortalityGHj for Covid–19: the epidemiological study. BMJ Yale medR. doi.org/10.1101/2020.03.24.200429373.
3. Freyne B, Marchant A, Curtis N. BCG-associated heterologous immunity, a historical perspective: intervention studies in animal models infection diseases. Trans R. Soc. Trop. Med. Hyg. 2015;109(1):52–61. https://doi.org/10.1093/trstmh/tru197.
4. de Bree C, Marijnissen RJ, Kel JM, et al. Bacillus Calmett-Querin-induced trained immunity is not protective for experimental influenza A/Anhui/1/2013(H7N9) infection in mice. Front. Immunol. 2018; Publ. 30 April. https://doi.org/10.3389/fimmu.2018.00869.
5. Zimmermann P, Finn A, Curtis N. Does BCG Vaccination Protect Against Nontuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis. The Journal of Infectious Diseases. 2018;218(5):679–687. https://doi.org/10.1093/infdis/jiy207.
6. Hippmann G, Wekkeli M, Rosenkranz AR, et al. Nonspecific immune stimulation with BCG in Herpes simplex recidivans. Follow-up 5 to 10 years after BCG vaccination//Wien Klin Wochenschr.1992;104(7):200–204. http://www.ncbi.nlm.nih.gov/pubmed/1523844PMID:1523844er/1_BCG_report_revised_version_online.pdf
7. Arts RJW, Moorlag SJCFM., Novakovic B, et al. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host et Microbe. 2018;.23(1):89–100.e5. https://doi.org/10.1016/j.chrom.2017.12.0106.
8. Aaby, Roth A, Ravn H, et al. Randomized trial of BCG vaccination–at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? Pediatr. Infect. Dis. Journ. 2011;204:245–252. doi: 10.1093/infdis/jir240
9. Curtis N. BCG vaccination and all cause neonatal mortality. Pediatr. Infect. Dis. Journ. 2019;38(2):195–197. DOI: 10.1097/INF.0000000000002230.
10. Berendsen MLT, Bjerregård ChO, Bles P, et al. Maternal priming Bacillus Calmette-Guerin (BCG) vaccine scarring in mothers enhances the survival of their child with a BCG vaccine scar. J. Pediatr. Infect. Dis. Soc. 2020;9:166–172. https://doi.org/10.1093/jpids/piy142 Published: 03 February 2019.
11. Blok BA, Arts RJW, van Crevel R, et al. Differential effects of BCG vaccine on immune responses induced by Vi polysaccharide typhoid fever vaccination: an explorative ran- domized trial. Eur J Clin Microb Infect Dis. 2020; 39:1177–1184. doi.org/10.1007/s10096-020-03813-y. Accepted: 12 January 2020 /Published online: 17 February.
12. Salman S, Salem ML. Routine immunization may protect childhood against COVID-19. Med Hypoteses. 2020; Mar 25 (1-serial number 5):11–13. doi:10.21608/jcbr.2020. mar 25 doi:10.1016/jmehy.2020.109689. PMCID: PMC727057979 PMID:32240961.
13. Gursel M, Gursel I. Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic? Med Hypotheses. 2020; Apr 6. PMCID:PMC7136957 https://doi.org/1.10.1016/j.mehy.2020.109707
14. Dayal D, Gupta S. Connecting BCG vaccination and COVID-19. medRxiv preprint. https://doi.org/10.1101/2020.04.07.20053272
15. Curtis N, Sparrow A, Ghebreyesus TA, al. Considering BCG vaccination to reduce the impact of COVID-19. Publ. shed Online April 30, 2020; https://doi.org/10.1016/S0140-6736(20)31025-4
16. Macedo A, Febra C. Relation between BCG coverage rate and COVID-19 infection worldwide. Med Hypotheses 2020;142:109816. PMCID:PMC7201219 PMID:32408. https://doi.org/10.1016/j.mehy.109816
17. Fuge O, Vasdev N, Allchorne P, et al. Immunotherapy for bladder cancer//Res Rep Urol 2015;7:65–79. doi.org/10.2147/rru.s63447
18. Sharquie KE, Al-Rawi JR, Al-Nuaimy AA, et al. Bacille Calmette-Guerin immunotherapy of viral warts//Saudi Med J. 2008; 29(4):589–593.
19. Sharquie KE, Al-Rawi J, Nuaimi A., et al. Tuberculin as Intralesional Therapy for Viral Warts – Single-Blind, Split, Placebo, Controlled Study. Jurnal of Cosmetics, Dermatological Sciences and Applications. 2016; 6(5):191–198. https://doi.org/10.4236/jcdsa.2016.65024
20. Sharquie IK. BCG is a Good Immunotherapeutic Agent for Viral and Autoimmune Diseases: Is it a New Weapon against Coronavirus (COVID-19)? Electronic Journal of General Medicine 2020; 17(6): em229 e: 2516–3507. https://doi.org/10.29333/ejgm/7892.
21. Panigrahi P, Parida S, Nanda NC, et al. A randomized synbiotic trial to prevent sepsis among infants in rural India//Nature. 2017;(548):407–412.
22. Higgins JPT, Soares-Weiser K, Lopez-Lopez JA, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016;(355):51–70.
23. Bekkering S, Blok BA, Joosten LAB, et al. In vitro experimental model of trained innate immunity in human primary monocytes. Clin vaccine immunol. 2016. Doi: 10.1128/CVI.00349-16
24. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via genetic reprogramming of monocytes. PNAS. October 23. 2020;109:17537–17542. doi.org/10.1073/pnas.1202870109.
25. Flanagan KL, van Crevel R, Curtis N, et al. Optimmunize Network. Heterologous («nonspecific») and sex-differential effects of vaccines: epidemiology, clinical trials, and emerging immunologic mechanisms. Clin Infect Dis. 2013;57:283–289.
26. Goodridge HS, Ahmed SSl, Curtis N, et al. Harnessing the beneficial heterologous effects of vaccination. Publi 09 May 2016;Nature Reviews Immunology. 2016; 16:392–400.
27. Arts RJW, Netea MG. Epigenetic rewiring of monocytes in BCG vaccination. In: The value of BCG and TNF in autoimmunity (Second Edition). Ed.: Faustman DL. Chapter 8 ELSEVIER Academic Press 2018;109–120. https://doi.org/10.1016/B978-0-12-814603-3.00008-2
28. O'Neil LAJ, et al, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. 2020; 20:335–337 https://doi.org/10.1038/s41577-020-0337-y.
29. Kleinnijenhuis J,·Quintin J,·Preijers F, et al. Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity. J. Immune 2014;6:152–158.
30. Freine B, Donath S, Kaya G, et al. Neonatal BCG vaccination influences cytokine responses to Toll-like receptor ligand and heterologous antigens. J. Inf Dis. 2018; 217(11):798-1808 doi.org10.1093/infdis/jiy069
31. Ayoub BM. COVID-19 vaccination clinical trials should consider multiple doses of BCG. Pharmazie. 2020;75(4):159. Apr. 6 2020. doi: 10.1691/ph.2020.0444.
32. Blok BA, Jensen KJ, Aaby P, et al. Opposite effects of Vaccinia and modified Vaccinia Ankara on trained immunity. Eur J Clin Microbiol Infect Dis. 2019;38(3):449–456. DOI:10.1007/s10096-018-03449-z PMID: 30719592
33. Cheung ChY, Poon LLM, Ng IHY, et al. Cytokine responses in severe acute respiratory syndrome Coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J. virol. 2005; doi:10.1128/jvi.79.12.7819-7826.2005
34. Lau SK, Lau CC, Chan KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J. Gen. Virol. 2013;94(12): First Publ 01 December 2013. https://doi.org/10.1099/vir.0.055533-0.
35. Chu H, Chan J Fuk-Woo, Yuen T. TSZ-Tai, et al. Comparative tropism., replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-Co with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. The Lancet Microbe. 2020;1(1):e14–e23. https://doi.org/10.1016/S2666-5247(20)30004-5 Get rights and content
36. Johnson BS, Laloraya M. A cytokine super cyclone in COVID-19 patients with risk factors; the therapeutic potential of BCG immunization. Cytokine and Growth Factor Reviews.Available online 1 july 2020. In Press https://doi.org/10.1016/j.cytogfr.2020.06.014.
37. Каральник Б. В., Разбаш М. П., Ахметова Е. А. Фосфолипидные антигены бактерий и их таксономическое значение. Журнал Гигиены, Эпиемиологии, Микробиологии и Иммунологии. Прага. 1981.25 (2):163–170.
38. Ахматова Н. К., Кимилевский М. В. Врожденный иммунитет противоопухолевый и противоинфекционный. Москва: Практическая медицина; 2008. 256 С.
39. Петров Р. В., Хаитов Р. М. Иммуногены и вакцины нового поколения. Москва: «ГЭОТАР-Медиа»; 2011. 608 С.
40. Rusek P, Wala M, Druszcsynska M, et al. Infectious agents as stimuli of trained innate immunity. Int J Mol Sci 2018; 19(2):456. doi.org/10.3390/ijms19020456.
41. Bartlet S, Skwarczynski M, Toth I. Lipids as activators of innate immunity in peptide vaccine delivery. Current Med Chemistry. 2018. https://doi.org/10.2174/0929867325666181026100849.
42. Giannini SL, Hanon PM, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 14 August 2006; 24(33–34):5937–5949. https://doi.org/10.1016/j.vaccine.2006.06.005
43. Levie K, Gjorup I, Skinhoj MA. 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix B in healthy young adults. Scand. J. Infect. Dis.2002; 34(8):610–614. Publ. online: 08 Jul 2009 https://doi.org/10.1080/00365540110080881
44. Boland G, Beran J, Lievens M, et al. Safety and immunogenicy profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine. 2004; 23(3):316–320. https://doi.org/10.1016/j.vaccine.2004.06.006.
45. Hernandez A, Bohannon JK, Luan L, et al. The role of MyD88-and TRIF-dependent signaling in monophosphoryl lipid A-induced expansion and recruitment of innate immunocytes//J. Leukocyte Biology. 2016;100(6):1311–1322. doi.org/1o.1189/jib.1A0216-072R.
46. Richard K, Mann BJ, Qin A, et al. Monophosphoryl lipid A enhances efficacy of Francisella LVS-cationic nanoparticle subunit vaccine against F. tularensis Schu S4 challenge by augmenting both humoral and cellular immunity. Clinical and Vaccine Immunology. 2017; 24(3):e00574–16. DOI:10.1128/cvi.00574-16.
47. Bae E-H, Seo SH, Rim C, et al. Bacterial outer membrane vesicles provide broad-spectrum protection against Influenza virus infection via recruitment and activation of mac- rophages. J. innate immun. 2019; 1:316–329. https://doi.org/10.1159/000494098.
48. Eun-JuKo, Lee Y, Lee Y-T, et al. MPL and CpG combination adjuvants promote homologousand heterosubtypic cross protection of inactivated split influenza virus vaccine. Antiviral Research. 2018; 156:107–115 https://doi.org/10.1016/j.antiviral.2018.06.004.
49. Molinaro A, Holst O, Di Lorenzo F, et al. Chemistry of Lipid A: At the Heart of Innate Immunity. Chemistry Europe. 2014; 21(2). First publ. 29 October 2014. https://doi.org/10.1002/chem.201403923.
50. Sancez-Ramon S, Conejero L, Netea MG, et al. Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious formulation. Front Immunol. 2018; 9 Article 2936.
51. WHO, EUR/RC65/17 Tuberculosis action plan for the WHO European Region 2016–2020. Доступно на: https://www.euro.who.int/__data/assets/pdf_file/0007/283804/65wd17e_Rev1_TBActionPlan_150588_withCover.pdf.
52. Thaiss ChA, Zmora N, Levy M, et al. The microbiome and innate immunity. Nature. 2016;(535):65–74.
53. Cергиев В. П., Пальцев М. А. Физиология паразитизма и проблема биологической безопасности. Москва: Издательство «Медицина», Издательство «ШИК» 2008. 144 С.
54. Харченко Е. П. Распространенность генетических рекомбинаций между вирусами и человеком, возможное их влияние на вакцинацию. Эпидемиология и вакцинопрофилактика. 2019;6:4–14.
55. O,Connor E, The J, Ashish M, et al. Bacillus Calmette G. (BCG) vaccination use in the fight against COVID-19 – what's old is new again? Future Medicine. Future oncology. 2020;16(19): commentary. Publ. Online 14 May https://doi.org102217/fon2020-0381on-0381.
56. Johnson BS, Laloraya M A cytokine super cyclone in COVID-19 patients with risk factors:the therapeutic potential of BCG immunization. tokine &Growth Factor Reviews. https://doi.org/10.1016/j.cytogfr.2020.06.014.
